Roche said it plans to start a Phase 2 trial this year testing an obesity-drug combination of petrelintide and enicepatide. The company framed the pairing as an opportunity to combine a safety-focused obesity asset with another shot at efficacy. The announcement adds to a crowded obesity landscape where next-gen injectables and combinations are being explored to improve weight-loss durability and tolerability. For investors and clinicians, starting combination trials is a concrete step toward establishing whether dual-agent pharmacology can outperform monotherapy. Roche’s timeline will be watched closely for early safety, tolerability, and dose selection inputs that typically drive subsequent Phase 2 expansion design.